Loading...
•
Apr 01, 2023
Bioventus Q1 2023 Earnings Report
Reported financial results for the three months ended April 1, 2023.
Key Takeaways
Bioventus reported net sales of $119.1 million, a 1.5% increase year-over-year, with a net loss from continuing operations of $100.0 million. Adjusted EBITDA exceeded expectations at $17.0 million, compared to $7.2 million in the prior-year period.
Net Sales of $119.1 million, up 1.5% year-over-year as reported (1.9% constant currency).
Net Loss from continuing operations of $100.0 million, compared to Net Loss from continuing operations of $14.4 million in prior-year period.
Adjusted EBITDA of $17.0 million, compared to $7.2 million in prior-year period, exceeding the Company's expectations.
Signed a Purchase Agreement on May 10, 2023 to divest of Wound Business, which is expected to enhance liquidity and enable a greater focus on execution within the remaining business
Forward Guidance
The company is confident in achieving Adjusted EBITDA of at least $68 million for fiscal 2023. This outlook excludes the Wound Business, with annual revenues of approximately $40 million, and Adjusted EBITDA of approximately $5 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...